Article Data

  • Views 514
  • Dowloads 117

Original Research

Open Access

Expression of the PI3K/AKT/mTOR pathway as a prognostic factor in patients with advanced high grade serous ovarian carcinoma treated with neoadjuvant chemotherapy

  • S. Cierniak1
  • R. Koktysz1
  • M. Jesiotr1
  • A. Gąsowska-Bodnar2
  • L. Bodnar3,*,

1Department of Pathology, Military Institute of Medicine, warsaw, Poland

2Department of Gynecology and Gynecologic Oncology, Military Institute of Medicine, warsaw, Poland

3Department of Oncology, Military Institute of Medicine, warsaw, Poland

DOI: 10.12892/ejgo4575.2019 Vol.40,Issue 5,October 2019 pp.744-751

Accepted: 08 March 2018

Published: 10 October 2019

*Corresponding Author(s): L. Bodnar E-mail: lubo@esculap.pl

Abstract

Background: The aim of this study was to search biomarkers in patients with high grade serous ovarian carcinoma (HGSOC) treated with neoadjuvant chemotherapy (NACT) among the components of PI3K/AKT/mTOR pathway. Material and Methods: The authors assessed 49 patients with HGSOC (FIGO IIIC-IV) treated with NACT. The expression of PI3KCA, PTEN, pAKT473, mTOR, and p70S6K were assessed immunohistochemically. Results: The expression of PI3KCA and p70S6K in tumour tissue after NACT was significantly decreased compared to before chemotherapy (p = 0.0005 and p = 0.0256, respectively). Multivariate analysis demonstrated that high mTOR expression, suboptimal range of interval debulking surgery (IDS), platinum resistance, and the lack of paclitaxel in the NACT were independent adverse prognostic factors (HR= 3.86, 95% CI (1.75-8.56); HR= 3.94, 95% CI (1.76-8.83); HR= 2.29, 95% CI (1.13-4.64); and HR= 4.76, 95% CI (1.80-12.59), p < 0.05). Conclusions: The mTOR expression may be an independent prognostic factor, but further investigations are needed.

Keywords

High grade serous ovarian carcinoma; PI3K/AKT/mTOR pathway; Neoadjuvant chemotherapy

Cite and Share

S. Cierniak,R. Koktysz,M. Jesiotr,A. Gąsowska-Bodnar,L. Bodnar. Expression of the PI3K/AKT/mTOR pathway as a prognostic factor in patients with advanced high grade serous ovarian carcinoma treated with neoadjuvant chemotherapy. European Journal of Gynaecological Oncology. 2019. 40(5);744-751.

References

[1] ICancer Genome Atlas Research Network: “Integrated genomic analyses of ovarian carcinoma”. Nature, 2011, 474, 609.

[2] Mabuchi S., Kuroda H., Takahashi R., Sasano T.: “The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer”. Gynecol. Oncol., 2015, 137, 173.

[3] Dobbin Z.C, Landen C.N.: “The Importance of the PI3K/AKT/ MTOR Pathway in the Progression of Ovarian Cancer”. Int. J. Mol. Sci., 2013, 14, 8213.

[4] Sato S., Itamochi H.: “Neoadjuvant chemotherapy in advanced ovarian cancer: latest results and place in therapy”. Ther. Adv. Med. Oncol., 2014, 6, 293.

[5] Rutten M.J., Sonke G.S., Westermann A.M., van Driel W.J., Trum J.W., Kenter G.G., et al.: “Prognostic Value of Residual Disease after Interval Debulking Surgery for FIGO Stage IIIC and IV Epithelial Ovarian Cancer”. Obstet. Gynecol. Int., 2015, 2015, 464123.

[6] Wright A.A., Bohlke K., Armstrong D.K., Bookman M.A., Cliby W.A., Coleman R.L., et al.: “Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline”. Gynecol. Oncol., 2016, 143, 3.

[7] Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al.: “New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)”. Eur. J. Cancer Oxf. Engl., 1990, 2009, 45, 228.

[8] Janku F., Kaseb A.O., Tsimberidou A.M., Wolff R.A., Kurzrock R.: “Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing”. Oncotarget, 2014, 5, 3012.

[9] Hirashima K., Baba Y., Watanabe M., Karashima R-I., Sato N., Imamura Y., et al.: “Aberrant activation of the mTOR pathway and antitumour effect of everolimus on oesophageal squamous cell carcinoma”. Br. J. Cancer, 2012, 106, 876.

[10] Trigka E.A., Levidou G., Saetta A.A., Chatziandreou I., Tomos P., Thalassinos N., et al.: “A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: Correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features”. Oncol. Rep., 2013, 30, 623.

[11] Bostner J., Karlsson E., Pandiyan M.J., Westman H., Skoog L., Fornander T., et al.: “Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit”. Breast Cancer Res. Treat., 2013, 137, 397.

[12] Mahdi H., Xiu J., Reddy S.K., DeBernardo R.: “Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma”. J. Surg. Oncol., 2015, 112, 188.

[13] Bakkar R.M., Xie S-S., Urbauer D.L., Djordjevic B., Vu K., Broaddus R.R.: “Intact PTEN Expression by Immunohistochemistry is Associated With Decreased Survival in Advanced Stage Ovarian/Primary Peritoneal High-grade Serous Carcinoma”. Int. J. Gynecol. Pathol., 2015, 34, 497.

[14] Wang L., Wang C., Jin S., Qu D., Ying H.: “Expression of NF-κB and PTEN in primary epithelial ovarian carcinoma and the correlation with chemoresistance”. Int. J. Clin. Exp. Pathol., 2015, 8, 10953.

[15] Lee Y-K., Park N-H.: “Prognostic value and clinicopathological significance of p53 and PTEN in epithelial ovarian cancers”. Gynecol. Oncol., 2009, 112, 475.

[16] No J.H., Jeon Y-T., Park I-A., Kim Y-B, .Kim J.W., Park N-H., et al.: “Activation of mTOR signaling pathway associated with adverse prognostic factors of epithelial ovarian cancer”. Gynecol. Oncol., 2011, 121, 8.

[17] Wang S., Sun Y., He A., Zheng C., Zheng X.: “Predictive value of phosphorylated mammalian target of rapamycin for disease-free survival in breast cancer patients receiving neoadjuvant chemotherapy”. Oncol. Lett., 2014, 8, 2642.

[18] Marques A.E.M., Elias S.T., Porporatti A.L., Castilho R.M., Squarize C.H., De Luca Canto G., et al.: “mTOR pathway protein immunoexpression as a prognostic factor for survival in head and neck cancer patients: a systematic review and meta-analysis”. J. Oral Pathol. Med., 2016, 45, 319.

[19] Xiao L, Wang YC, Li WS, Du Y. The role of mTOR and phosphop70S6K in pathogenesis and progression of gastric carcinomas: an immunohistochemical study on tissue microarray. J. Exp. Clin. Cancer Res. CR. 2009;28:152.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top